Bioporto A/s · OMXCOP:BIOPOR
Bioporto A/s — Q3 2025 Earnings Presentation
12 slides from Bioporto A/s's earnings presentation, Nov 6, 2025
Slide 1: Transforming Care Through Actionable Kidney Biomarkers
BioPorto Transforming Care Through Actionable Kidney Biomarkers Business Strategy Update & Pre-announced Q3 2025 Financials November 6, 2025 CONFIDENTIAL | © Copyright BioPorto | 1
Slide 2: Forward-looking statements
Forward-looking statements References herein to this presentation shall mean and include this document, any oral presentation accompanying this document provided by BioPorto A/S (the “Company” or “BioPorto”), and any further information that may be made available in connection with the subject matte
Slide 3: The "Forward" Strategic Plan
The ”Forward” Strategic Plan Focus on Execution of Market Access & Commercialization to transform kidney care Aspirations 1 Adaption +60 US Hospitals 2H 2027 Cash + Validation Study flow Positive 2026 High +100 Global Hospitals FY 2028 Revenue 2 Growth + Adult Indication 2027 150-200m DKK +170 Globa
Slide 4: Market Access
Market Access Strengthen & accelerate execution Adult Indication Standard of Care Instrument Expansion ✓ Adult Clinical Study Ongoing ✓ Guideline organizations to ✓ Instrument expansion ✓ Expect to obtain FDA include biomarkers ✓ Enter further distribution clearance in 2027 ✓ Prepare market educatio
Slide 5: Commercialization
Commercialization Execute diligently the pediatric focus & adult entry preparation in targets markets US EU Process & Messaging 7 1 • AKI champions 6 2 • Clinical Education • Lab Validation • Clinical Operation 3 5 4 • Health Economy • Operational Support • Account management Direct Focus Indirect C
Slide 6: Highlights for the third quarter of 2025
Highlights for the third quarter of 2025 TOTAL REVENUE (Q3 2025) ✓ A major milestone in the third quarter of 2025 was the delivery of the first DKK 10.4 million purchase order for ProNephroTM AKI (NGAL) for the US market, marking 7% increase compared to Q3 2024 the first step in the commercial launc
Slide 7: Continued NGAL growth in Q3 2025 vs Q3 2024
Continued NGAL growth in Q3 2025 vs Q3 2024 Revenue Q3 2025 vs Q3 2024, DKKm Revenue per quarter, DKKm 9M 2025 vs 9M 2024 US NGAL RUO +20% (+27%) ROW NGAL -87% Total revenue +7% (+10%) ProNephro AKI (NGAL) +2.1m DKK 28.7m +1% (+2%) 10.6 10.4 10.4 9.7 +5% 9.5 9.7 9.2 (+10%) 8.6 8.0 7.7 7.7 7.8 7.2 6.
Slide 8: NGAL Sales US continuing strong growth projection
NGAL Sales US continuing strong growth projection US NGAL RUO sales (accumulated 12 months rolling at constant exchange rates) 18 +24% 17 16.1 16 15.1 15 14.2 14 13.7 13.0 13 12.3 11.8 DKKm 12 11 10.1 10.2 10 8.7 9 7.9 8 7 6 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2
Slide 9: Revised Financial Guidance 2025
Revised Financial Guidance 2025 Total revenue in 2025 Adjusted EBITDA loss in 2025 DKK 40-45m DKK 75-80m (Previously DKK 45-50m) (Unchanged) CONFIDENTIAL | © Copyright BioPorto | 9
Slide 10: Sustainable and Attractive Financials towards 2028
Sustainable and Attractive Financials towards 2028 High revenue growth and EBITDA positive Total Revenue Growth, DKKm ASPIRATIONS TOWARDS 2028 Aspiration 150-200 Total NGAL Other 64%* • NGAL US growth 2021-2024 with a CAGR of 18% Guidance • NGAL with significant 40-45 growth potential towards 12.1 1
Slide 11: Funding
Funding FUNDING NEEDS • DKK 60 – 70 million is required until cash flow positive in second half of 2027 FUNDING TO MAINTAIN MOMENTUM • Finalize adult clinical trials to seek FDA clearance for ProNephro AKI NGAL • Maintain and further build up the commercial platform EXPLORING FUNDING OPTIONS • Multi
Slide 12: Invest in AKI Diagnostic - Invest in BioPorto
Invest in AKI Diagnostic - Invest in BioPorto Early detection of AKI (Acute Kidney Injury) represents a major unmet need1 BioPorto’s ProNephro AKI (NGAL) is the first FDA-cleared test for pediatric AKI assessment Defined pathway for FDA approval and commercial launch of ProNephro AKI (NGAL) for adul